ENTA

12.84

1.52% -0.32

Handel nachbörslich: 12.83 -0.010 -0.08%

Enanta Pharmaceuticals Inc (ENTA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$13.16

Offen:

$13.13

24-Stunden-Volumen:

276.57K

Relative Volume:

1.34

Marktkapitalisierung:

$373.97M

Einnahmen:

$69.21M

Nettoeinkommen (Verlust:

$-61.98M

KGV:

-4.9485

EPS:

-2.5947

Netto-Cashflow:

$-9.61M

1W Leistung:

-6.15%

1M Leistung:

-5.68%

6M Leistung:

-6.49%

1J Leistung:

+62.00%

1-Tages-Spanne:

$12.59

$13.32

1-Wochen-Bereich:

$12.59

$13.98

52-Wochen-Spanne:

$7.05

$17.15

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Firmenname

Enanta Pharmaceuticals Inc

Sektor

Healthcare (1089)

Branche

Biotechnology (604)

Telefon

617 607 0800

Adresse

4 KINGSBURY AVENUE, WATERTOWN, MA

Mitarbeiter

120

Twitter

@EnantaPharma

Nächster Verdiensttermin

2026-08-10

Neueste SEC-Einreichungen

ENTA's Discussions on Twitter

Compare ENTA vs VRTX, REGN, ARGX, RVMD, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ENTA Enanta Pharmaceuticals Inc	12.84	383.29M	69.21M	-61.98M	-9.61M	-2.5947
VRTX Vertex Pharmaceuticals Inc	515.57	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.86	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	986.80	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.94	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.66	39.31B	5.76B	514.49M	1.10B	4.4813

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-26	Eingeleitet	Rodman & Renshaw	Buy
2025-11-14	Eingeleitet	JP Morgan	Overweight
2025-10-01	Hochstufung	Jefferies	Hold → Buy
2025-07-28	Fortgesetzt	H.C. Wainwright	Buy
2023-08-09	Herabstufung	JP Morgan	Neutral → Underweight
2023-08-08	Herabstufung	Jefferies	Buy → Hold
2022-12-09	Eingeleitet	H.C. Wainwright	Buy
2022-07-06	Hochstufung	Evercore ISI	In-line → Outperform
2022-06-01	Hochstufung	Evercore ISI	Underperform → In-line
2021-10-07	Eingeleitet	Jefferies	Buy
2021-09-09	Eingeleitet	SVB Leerink	Mkt Perform
2021-01-29	Hochstufung	JP Morgan	Underweight → Neutral
2020-11-24	Eingeleitet	Evercore ISI	Underperform
2020-08-28	Fortgesetzt	ROTH Capital	Buy
2020-08-26	Eingeleitet	Piper Sandler	Overweight
2020-07-27	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2020-03-17	Hochstufung	Robert W. Baird	Neutral → Outperform
2019-11-22	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2019-09-26	Herabstufung	JP Morgan	Neutral → Underweight
2019-05-24	Eingeleitet	Wolfe Research	Outperform
2019-04-23	Hochstufung	Berenberg	Hold → Buy
2018-12-13	Eingeleitet	Berenberg	Hold
2018-06-06	Eingeleitet	ROTH Capital	Buy
2018-02-08	Herabstufung	JP Morgan	Overweight → Neutral
2018-01-02	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2017-11-21	Bestätigt	RBC Capital Mkts	Outperform
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2017-07-11	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2016-04-28	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Bestätigt	Barclays	Underweight
2015-10-23	Herabstufung	Barclays	Equal Weight → Underweight
2015-10-23	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform

Alle ansehen

Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten

Aug 14, 2026

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Share Price, ENTA Stock News, ENTA Share Price & Updates - kalkine.com.au

Aug 14, 2026

Aug 12, 2026

Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses - Sahm

Aug 12, 2026

Aug 11, 2026

H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20 - Moomoo

Aug 11, 2026

Aug 10, 2026

Enanta Pharma reports $19.5 million Q3 loss, advances RSV pipeline - scanx.trade

Aug 10, 2026

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates - NewsBreak: Local News & Alerts

Aug 10, 2026

Is Enanta Pharmaceuticals (ENTA) Overvalued After Q3 Earnings Mi - GuruFocus

Aug 10, 2026

Enanta Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Enanta Pharma misses Q3 estimates on lower royalty revenue By Investing.com - Investing.com Canada

Aug 10, 2026

Enanta Fiscal Q3 2026 Earnings: Higher Royalty-Related Interest Expense Widens Net Loss - TradingKey

Aug 10, 2026

Enanta Pharma misses Q3 estimates on lower royalty revenue - Investing.com

Aug 10, 2026

Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Misses Expectations By $0.16 EPS - marketbeat.com

Aug 10, 2026

Enanta Pharmaceuticals reports Q3 loss; revenue $14.4M, cash and securities $211.5M - TradingView

Aug 10, 2026

Enanta Pharma On Track to File IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select MRGPRX2 Development Candidate, in 2H >ENTA - Moomoo

Aug 10, 2026

Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot - AOL.com

Aug 10, 2026

Press Release: Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2026 - Moomoo

Aug 10, 2026

Aug 07, 2026

Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView

Aug 07, 2026

Enanta Pharmaceuticals (ENTA) Climbs 3.2% as Shares Test Key Resistance at $14.46Market Profile - dars.gov.et

Aug 07, 2026

Aug 06, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Aug 06, 2026

(ENTA) Risk Channels and Responsive Allocation - Stock Traders Daily

Aug 06, 2026

Aug 03, 2026

Enanta Pharmaceuticals (ENTA) Expected to Post Quarterly Earnings on Monday - MarketBeat

Aug 03, 2026

Jul 30, 2026